Compare Dover Corp (DOV) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Illumina, Inc. — how do they compare? Dover Corp trades at $208.79 (market cap $28.07B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Dover Corp and Illumina, Inc. are close in size by market cap, and Dover Corp pays a 1.01% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DOV | ILMN | |
|---|---|---|
Market Cap | $28.07B | $29.12B |
Sector | Industrials | Health |
52-Week High | $233.31 | $205.10 |
52-Week Low | $161.16 | $91.00 |
Enterprise Value | $29.58B | $30.48B |
Dividend Yield | 1.01% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
